Gregg Gilbert
Stock Analyst at Truist Securities
(2.26)
# 2,671
Out of 5,114 analysts
84
Total ratings
53.7%
Success rate
5.38%
Average return
Main Sectors:
Stocks Rated by Gregg Gilbert
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DHT DHT Holdings | Maintains: Buy | $14 → $17 | $12.23 | +39.00% | 2 | Feb 16, 2024 | |
| COLL Collegium Pharmaceutical | Maintains: Buy | $31 → $37 | $48.88 | -24.30% | 1 | Jan 4, 2024 | |
| BMY Bristol-Myers Squibb Company | Reiterates: Buy | $84 | $54.19 | +55.01% | 9 | Sep 15, 2023 | |
| LLY Eli Lilly and Company | Maintains: Buy | $430 → $525 | $1,071.44 | -51.00% | 10 | Jul 20, 2023 | |
| EOLS Evolus | Maintains: Buy | $11 → $13 | $7.07 | +83.88% | 2 | Mar 4, 2022 | |
| NVCR NovoCure | Upgrades: Buy | n/a | $12.84 | - | 10 | Jan 20, 2022 | |
| MRK Merck & Co. | Maintains: Buy | $96 → $93 | $101.09 | -8.00% | 8 | Jun 7, 2021 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $38 → $48 | $28.01 | +71.37% | 2 | Feb 2, 2021 | |
| CHRS Coherus Oncology | Initiates: Buy | $26 | $1.36 | +1,811.76% | 1 | Apr 17, 2020 | |
| MTNB Matinas BioPharma Holdings | Initiates: Buy | $150 | $0.73 | +20,581.10% | 1 | Jan 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $93 → $78 | $13.23 | +489.57% | 17 | Aug 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $76 → $78 | $122.24 | -36.19% | 5 | Feb 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $20 → $18 | $30.35 | -40.69% | 6 | Feb 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $178 → $175 | $166.99 | +4.80% | 6 | Aug 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $65 → $66 | $226.82 | -70.90% | 4 | Jul 17, 2017 |
DHT Holdings
Feb 16, 2024
Maintains: Buy
Price Target: $14 → $17
Current: $12.23
Upside: +39.00%
Collegium Pharmaceutical
Jan 4, 2024
Maintains: Buy
Price Target: $31 → $37
Current: $48.88
Upside: -24.30%
Bristol-Myers Squibb Company
Sep 15, 2023
Reiterates: Buy
Price Target: $84
Current: $54.19
Upside: +55.01%
Eli Lilly and Company
Jul 20, 2023
Maintains: Buy
Price Target: $430 → $525
Current: $1,071.44
Upside: -51.00%
Evolus
Mar 4, 2022
Maintains: Buy
Price Target: $11 → $13
Current: $7.07
Upside: +83.88%
NovoCure
Jan 20, 2022
Upgrades: Buy
Price Target: n/a
Current: $12.84
Upside: -
Merck & Co.
Jun 7, 2021
Maintains: Buy
Price Target: $96 → $93
Current: $101.09
Upside: -8.00%
Arcutis Biotherapeutics
Feb 2, 2021
Maintains: Buy
Price Target: $38 → $48
Current: $28.01
Upside: +71.37%
Coherus Oncology
Apr 17, 2020
Initiates: Buy
Price Target: $26
Current: $1.36
Upside: +1,811.76%
Matinas BioPharma Holdings
Jan 24, 2020
Initiates: Buy
Price Target: $150
Current: $0.73
Upside: +20,581.10%
Aug 10, 2018
Downgrades: Hold
Price Target: $93 → $78
Current: $13.23
Upside: +489.57%
Feb 16, 2018
Maintains: Hold
Price Target: $76 → $78
Current: $122.24
Upside: -36.19%
Feb 9, 2018
Maintains: Hold
Price Target: $20 → $18
Current: $30.35
Upside: -40.69%
Aug 9, 2017
Maintains: Buy
Price Target: $178 → $175
Current: $166.99
Upside: +4.80%
Jul 17, 2017
Maintains: Hold
Price Target: $65 → $66
Current: $226.82
Upside: -70.90%